Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety

Publisher： Karger

E-ISSN： 1421-9735|41|1-3|166-170

ISSN： 0253-5068

Source： Blood Purification, Vol.41, Iss.1-3, 2016-01, pp. : 166-170

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vitamin K Antagonists Predispose to Calciphylaxis in Patients with End-Stage Renal Disease

By  

Nephron, Vol. 129, Iss. 3, 2015-02 ,pp. : 197-201

Karger

Access to resources Recommend Favorite

Angiotensin-Converting Enzyme Inhibitors but Not Angiotensin II AT 1 Receptor Antagonists Affect Erythropoiesis in Patients with Anemia of End-Stage Renal Disease

By  

Nephron, Vol. 81, Iss. 1, 1999-01 ,pp. : 106-108

Karger

Access to resources Recommend Favorite

Daily Hemofiltration for End-Stage Renal Disease: A Feasibility and Efficacy Trial

By  

Blood Purification, Vol. 22, Iss. 6, 2005-01 ,pp. : 481-489

Karger

Access to resources Recommend Favorite

Keloids and End-Stage Renal Disease

By  

Nephron, Vol. 80, Iss. 2, 1998-09 ,pp. : 244-246

Karger

Access to resources Recommend Favorite

Salt and Hypertension in End-Stage Renal Disease

By  

Blood Purification, Vol. 16, Iss. 6, 1999-05 ,pp. : 301-311

Karger

Access to resources Recommend Favorite